Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

NIAID

Drug and asset intelligence for NIAID with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
7
Catalysts
4
Stage
Development stage unavailable

Sponsor company

immunology therapeutics →

Recent signals(7)

ClinicalJuly 26, 2026

NIAID Study on HIV Pathogenesis Using Human Blood Cells

A study is underway to investigate the virologic and immunologic parameters of HIV infection using human peripheral blood cells.

ClinicalJuly 21, 2026

Phase 1 Trial of mRNA HIV Vaccines DV700P-RNA and DV701B1.1-RNA Initiated

A phase 1 trial is underway to assess the safety and immune response of two mRNA vaccines in HIV-positive adults.

ClinicalJuly 18, 2026

NIAID Initiates Phase A/B Trial for Experimental H1N1 Influenza Vaccine BPL-1357

The National Institute of Allergy and Infectious Diseases is testing an experimental flu vaccine, BPL-1357, in a two-phase clinical trial involving healthy adults.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(4)

Topline Data

— NIAID

July 18, 2026 · N/A

Topline Data

— NIAID

July 10, 2026 · N/A

Topline Data

— NIAID

July 6, 2026 · N/A

Topline Data

— NIAID

June 20, 2026 · N/A

Indications

Genetic Disorders →
Infectious Disease →
Inflammatory Disorders →
Influenza →

Therapeutic areas

Genetic Disorders →
HIV →
Immunology →
Immunology · Genetic Disorders →
Immunology · Inflammatory Disorders →
Infectious Disease →
Infectious Disease · Influenza →
Infectious Disease · Malaria →
Inflammatory Disorders →
Influenza →
Malaria →
Tuberculosis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ClinicalJuly 12, 2026

NIAID Launches Study on Natural History of Tuberculosis with Active Recruitment

The National Institute of Allergy and Infectious Diseases is recruiting individuals with active or latent tuberculosis for a study on the disease's natural history.

ClinicalJuly 10, 2026

Sanaria Inc. Initiates PfSPZ-LARC2 Vaccine Trial for Women in Mali

Sanaria Inc. is conducting a randomized trial to evaluate the safety and efficacy of the PfSPZ-LARC2 vaccine in women of child-bearing potential in Mali.

ClinicalJuly 6, 2026

NIAID Launches Study on Inflammatory Disorders with Long-Term Follow-Up

The NIAID is conducting a study to evaluate and follow up on patients with various inflammatory disorders, including infections and immune dysfunctions.

ClinicalJune 20, 2026

Study on Genetic Disorders of the Immune System Launched by NIAID

NIAID is conducting a study to evaluate individuals with specific immune system disorders, involving extensive genetic and medical assessments.